A retrospective, multicenter study of efficacy of anti-PD-1 monotherapy in patients with non-small cell lung cancer
Latest Information Update: 22 Sep 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Sep 2021 New trial record